Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

Virtual Diagnosis?

The AIDS virus’s ability to quickly mutate and become resistant to new drugs makes it difficult for doctors to choose medications that will work. Researchers at Virco Group in Oxford, England, have created a new tool to give doctors better information about viral drug resistance, allowing them to design effective therapies. Called Virtual Phenotype, the analysis takes the genetic code of a patient’s HIV strain and predicts the drugs it will be resistant to. The system, one of the earliest examples of pharmacogenomics in action, reportedly provides the first quantitative analysis of viral drug resistance. The analysis is quicker than actual phenotype testing, which involves growing virus and screening it with drugs, and costs up to three times less. Virco is developing similar databases for cancer and hepatitis B.

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.